Pharmacokinetics and excretion of dalbavancin in the rat
| Autor: | Luigi Colombo, Simona Riva, Marco Cavaleri, James A. Dowell, Martin Stogniew, Marco Guanci, Anna Valagussa |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Microbiology (medical) medicine.medical_specialty Urine Pharmacology Biology Rats Sprague-Dawley Excretion Pharmacokinetics Internal medicine medicine Animals Tissue Distribution Pharmacology (medical) Feces Antibacterial agent Glycopeptides Dalbavancin Half-life Glycopeptide Anti-Bacterial Agents Rats Infectious Diseases Endocrinology Area Under Curve Teicoplanin Half-Life |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 55:ii31-ii35 |
| ISSN: | 1460-2091 0305-7453 |
| Popis: | Objectives: The pharmacokinetics, tissue distribution and excretion routes of dalbavancin, a semi-synthetic glycopeptide, were investigated in rats. Methods: A 20 mg/kg intravenous dose of dalbavancin or [ 3 H]dalbavancin was administered to rats in three studies. Concentrations of dalbavancin or drug-derived radioactivity were assessed in blood, plasma, tissues, bile, urine and faeces by HPLC-MS/MS, scintillation counting or microbiological methods. Results: Dalbavancin decayed tri-exponentially in plasma with an apparent terminal t 1/2 of 187h (approximately 8 days). Dalbavancin has dual routes of elimination, with around two-thirds of the excreted drug-derived radioactivity being found in the urine and around one-third in the faeces. After 70 days, 44.2% and 22.3% of the drug-derived radioactivity had been recovered in the urine and faeces, respectively. Biliary excretion of drug-derived radioactivity accounted for over half of the radioactivity excreted faecally. At 70 days post-dose |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|